Teva Pharmaceutical Industries Limited
- Open
- 33.89
- Day high
- 33.99
- Day low
- 33.27
- Prev close
- 33.88
- Volume
- 1.2M
- Mkt cap
- $38.7B
- P/E (TTM)
- 24.2
- EPS (TTM)
- $1.39
- P/B
- 4.7
- P/S
- 2.2
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$18.9M over the last 3 months (0 open-market buys, 11 sales)
- 🏛Institutions accumulating (13F)
Teva Pharmaceutical Industries Limited (TEVA) is a Healthcare company listed on NYSE. The stock is up 98% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 11 sales (SEC Form 4).
Teva Pharmaceutical Industries Limited (TEVA) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 6 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
TEVA earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Apr 29, 2026 | $0.50 | $0.53 | +6.0% | $4.0B | +5.1% |
| Jan 28, 2026 | $0.65 | $0.96 | +47.7% | $4.7B | +21.7% |
| Nov 5, 2025 | $0.68 | $0.78 | +14.7% | $4.5B | +0.6% |
| Jul 30, 2025 | $0.63 | $0.66 | +4.8% | $4.2B | -4.3% |
| Jan 29, 2025 | $0.69 | $0.71 | +2.9% | $4.2B | +3.0% |
| Jul 31, 2024 | $0.57 | $0.61 | +7.0% | $4.2B | +1.6% |
| Jan 31, 2024 | $0.75 | $1.00 | +33.3% | $4.5B | +10.7% |
| Nov 8, 2023 | $0.60 | $0.60 | +0.0% | $3.9B | +3.1% |
| Aug 2, 2023 | $0.54 | $0.56 | +3.7% | $3.9B | +4.4% |
| Feb 8, 2023 | $0.68 | $0.71 | +4.4% | $3.9B | -0.1% |
| Nov 3, 2022 | $0.61 | $0.59 | -3.3% | $3.6B | -6.4% |
| Jul 26, 2022 | $0.57 | $0.68 | +19.3% | $3.8B | +0.3% |
TEVA insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 22, 2026 | Shields Matthewofficer: EVP, Global Operations | Sell | 9,989 | $32.19 |
| Jun 16, 2026 | Kalif Eliyahu Sharonofficer: EVP, Chief Financial Officer | Sell | 106,563 | $34.10 |
| Jun 8, 2026 | Francis Richard Dofficer: President and CEO | Sell | 6,153 | $34.35 |
| Jun 8, 2026 | Zaks Tal Zvidirector | Option | 14,492 | — |
| Jun 8, 2026 | BARER SOL Jdirector | Option | 21,739 | — |
| Jun 8, 2026 | Elstein Amirdirector | Option | 14,492 | — |
| Jun 8, 2026 | MIGNONE ROBERTOdirector | Option | 14,492 | — |
| Jun 8, 2026 | Satchi-Fainaro Ronitdirector | Option | 14,492 | — |
| Jun 8, 2026 | Lichtenstein Chendirector | Option | 14,492 | — |
| Jun 8, 2026 | Francis Richard Dofficer: President and CEO | Option | 13,043 | — |
| Jun 8, 2026 | Crane Rosemary Adirector | Option | 14,492 | — |
| Jun 8, 2026 | LIEBERMAN GERALD Mdirector | Option | 14,492 | — |
| Jun 8, 2026 | Nisen Perrydirector | Option | 14,492 | — |
| Jun 4, 2026 | Shields Matthewofficer: EVP, Global Operations | Option | 16,195 | — |
| Jun 4, 2026 | Shields Matthewofficer: EVP, Global Operations | Sell | 16,195 | $32.87 |
Source: TEVA SEC Form 4 filings, latest Jun 22, 2026. For informational purposes only — not investment advice.
See the full TEVA insider & 13F page →Teva Pharmaceutical Industries Limited company profile
Overview
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is an Israeli multinational pharmaceutical company founded in 1901 and headquartered in Tel Aviv-Yafo, Israel. Originally established as a small wholesale drug business, Teva has evolved into one of the world's largest generic drug manufacturers and a significant player in specialty pharmaceuticals. The company went public on NASDAQ in 1982 and has grown through strategic acquisitions and organic expansion to become a global pharmaceutical powerhouse operating in North America, Europe, and international markets. Today, Teva is undergoing a strategic transformation from a primarily generics-focused company to a more balanced biopharmaceutical enterprise with growing innovative drug portfolios.
Business
Teva operates in the pharmaceutical industry, which involves the research, development, manufacturing, and commercialization of medicines to treat various diseases and medical conditions. The company operates across three main business segments that collectively generated $16.5 billion in revenue in 2024. The Generics business represents Teva's largest segment, accounting for approximately 57% of total revenue ($9.5 billion in 2024). Generic drugs are bioequivalent versions of brand-name medications that become available after the original drug's patent expires. These medicines contain the same active ingredients and work identically to their brand-name counterparts but are sold at significantly lower prices. Generics help reduce healthcare costs by providing affordable treatment options. Teva manufactures a wide range of generic medications including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams across multiple therapeutic areas. The Innovative Products business comprises approximately 25% of revenue and focuses on proprietary branded medications that Teva has developed or acquired. Key products include AUSTEDO ($1.6 billion in 2024 sales), a treatment for movement disorders like tardive dyskinesia and Huntington's disease chorea; AJOVY ($500 million in sales), a preventive migraine treatment; and UZEDY ($80 million in sales), a long-acting injectable antipsychotic for schizophrenia. The company also markets respiratory medications like ProAir and QVAR for asthma and COPD, as well as oncology treatments. The Active Pharmaceutical Ingredients (API) business, known as TAPI, represents the remaining revenue and manufactures the raw chemical compounds used in drug production. These ingredients are sold to other pharmaceutical companies for their own drug manufacturing. However, Teva has announced plans to divest this business segment to focus on its core pharmaceutical operations. Additionally, Teva is expanding its biosimilars portfolio, which are near-identical copies of complex biologic drugs. The company has launched biosimilar versions of expensive treatments like Humira and is developing biosimilars targeting nearly $60 billion in brand-name biologic sales.
Revenue model
Teva generates revenue through multiple business models across its pharmaceutical portfolio. The generics business operates on a high-volume, low-margin model where the company manufactures and sells generic versions of off-patent drugs to pharmacies, hospitals, and healthcare systems. Revenue comes from direct product sales, with pricing typically 80-90% below the original brand-name drug. Success depends on manufacturing efficiency, supply chain optimization, and the ability to quickly launch generic versions when patents expire. The innovative products business follows a traditional pharmaceutical model with higher margins, generating revenue through direct sales of proprietary branded medications to healthcare providers, pharmacies, and patients. These drugs command premium pricing due to patent protection and clinical differentiation. Key customers include specialty pharmacies, hospitals, and healthcare systems that treat patients with specific conditions like movement disorders, migraines, and psychiatric conditions. The biosimilars business represents a hybrid model, offering lower-cost alternatives to expensive biologic drugs while maintaining higher margins than traditional generics due to the complexity of manufacturing and regulatory barriers to entry. Several factors influence Teva's profitability margins. Positive margin drivers include the growing sales of high-margin innovative products like AUSTEDO, which is experiencing strong demand growth; successful launches of complex generics and biosimilars that face limited competition; operational efficiency improvements through manufacturing site consolidations and automation; and the company's scale advantages in procurement and distribution. Negative margin pressures come from intense generic drug pricing competition as more manufacturers enter markets; regulatory compliance costs and quality requirements; patent cliff risks when innovative products lose exclusivity; raw material cost inflation; and significant R&D investments required for pipeline development. The company is also managing substantial debt service costs from past acquisitions, though debt levels have been declining. Teva targets achieving a 30% operating margin by 2027 through its strategic transformation focused on innovative products and operational improvements.
Competitive moat
Teva's competitive moat is moderate but improving as the company transitions from generics to innovative pharmaceuticals. In the generics business, Teva's moat is relatively narrow, relying primarily on manufacturing scale, regulatory expertise, and distribution relationships. The company benefits from its global manufacturing footprint, extensive regulatory approval database, and established relationships with major pharmacy chains and healthcare systems. However, generic drugs are commoditized products with limited differentiation, making this segment vulnerable to pricing pressure and new entrants. The company's strongest moat elements emerge from its innovative products portfolio. AUSTEDO benefits from significant barriers to entry due to complex manufacturing requirements, specialized sales force relationships with movement disorder specialists, and strong clinical data. The drug addresses a large underdiagnosed patient population (only 120,000 of 785,000 estimated patients are currently diagnosed), providing substantial growth runway. AJOVY competes in the competitive migraine prevention market but benefits from differentiated dosing and delivery mechanisms. Teva's biosimilars business represents a developing moat based on regulatory expertise, manufacturing capabilities for complex biologics, and early-mover advantages in specific therapeutic areas. The company's partnership with Alvotech provides access to a broad biosimilars pipeline targeting high-value biologics. Competitive threats include large pharmaceutical companies with greater R&D resources competing in innovative products; biosimilar specialists like Amgen and Sandoz with stronger biologic manufacturing capabilities; and generic manufacturers in low-cost countries pressuring traditional generics pricing. The company's substantial debt burden also limits financial flexibility compared to competitors. The moat is strengthening as Teva's innovative products grow and the company advances its pipeline in neuroscience and immunology, but remains vulnerable to patent expirations and competitive pressures across all business segments.
Risks & safety
Teva's margin of safety appears moderate to concerning based on current financial metrics, though the company has been improving its financial position. **Debt and Solvency:** - Net debt of $15.7 billion with debt-to-equity ratio of 2.7x, indicating high leverage - Net debt-to-EBITDA ratio improved to 3.0x, down from higher levels but still elevated - Cash and short-term investments of $1.7 billion provide limited liquidity cushion - Current ratio of 1.03 indicates tight working capital position - Free cash flow turned negative at -$232 million in Q1 2025, concerning trend **Valuation Metrics:** - EV/EBITDA of 10.7x appears reasonable for pharmaceutical sector - Price-to-earnings ratio of 20.4x seems elevated given growth challenges - Price-to-book ratio of 2.8x reflects asset base but high debt levels - Graham number suggests potential undervaluation, but debt concerns persist **Other Considerations:** - Company has received credit rating upgrades from major agencies, indicating improving creditworthiness - Strong cash generation capability in prior periods ($749 million free cash flow in 2024) - Substantial legal settlement obligations from opioid litigation creating ongoing cash outflows - Patent cliff risks for key products requiring successful pipeline execution
Recent development
Over the past few years, Teva has undergone a significant strategic transformation under its "Pivot to Growth" strategy, shifting from a generics-focused company to a more balanced biopharmaceutical enterprise. The strategy rests on four key pillars: delivering growth engines, stepping up innovation, creating a sustainable generics powerhouse, and focusing the business. Growth Engine Development: Teva has successfully built AUSTEDO into a $1.6 billion franchise through expanded indications, launch of once-daily AUSTEDO XR formulation, and increased physician awareness campaigns. The company is targeting $2.5 billion in AUSTEDO sales by 2027. AJOVY has grown to over $500 million globally, while the newer UZEDY launch for schizophrenia reached $80 million in its first full year. Innovation Pipeline Advancement: The company has made significant pipeline progress, including positive Phase III results for olanzapine LAI (long-acting injectable) for schizophrenia, which could become another blockbuster given the large unmet medical need. Teva's anti-TL1A program (Duvakitug) through partnership with Sanofi is preparing for Phase III trials in inflammatory bowel disease, targeting a $28 billion market opportunity. The company has also expanded its anti-IL-15 program to include vitiligo and celiac disease indications. Biosimilars Expansion: Teva has aggressively built its biosimilars portfolio, launching Humira biosimilar SIMLANDI and receiving approval for Stelara biosimilar. The company has 17 biosimilars in development targeting nearly $60 billion in brand sales, with seven planned U.S. launches and four European launches. Operational Optimization: The company has undertaken significant restructuring, closing manufacturing sites (reducing from 35 to below 30 by 2027), implementing automation, reducing organizational layers, and targeting $700 million in net savings by 2027. Teva has also announced plans to divest its TAPI (API) business to focus resources on core pharmaceutical operations. Financial Improvement: The company has consistently reduced net debt levels, improved credit ratings from all major agencies, and targets achieving 2x net debt-to-EBITDA ratio by 2027 alongside 30% operating margins.
TEVA company profile · for informational purposes only — not investment advice.
Track TEVA with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free